Keywords: Eculizumab; Atypical hemolytic uremic syndrome (aHUS); glucose-6-phosphate dehydrogenase (G6PD); eculizumab; misdiagnosis; chronic nonspherocytic hemolytic anemia (CNSHA); thrombocytopenia; acute kidney injury (AKI); case report;
مقالات ISI Eculizumab (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Eculizumab; Transplantation-associated thrombotic microangiopathy (TA-TMA); aHUS; Eculizumab;
Keywords: Eculizumab; Paroxysmal Nocturnal Hemoglobinuria; Eculizumab; Thrombosis; Aplastic anemia;
Keywords: Eculizumab; Eculizumab; Complement; C5 inhibitor; Soluble membrane attack complex; Alternative pathway; Complement C5 component;
Keywords: Eculizumab; cesarean section; complement; eculizumab; hemolytic uremic syndrome; postpartum;
Keywords: Eculizumab; Catastrophic antiphospholipid syndrome; Therapeutics; Anticoagulation; Corticoids; Plasma exchange; Intravenous immunoglobulins; Rituximab; Eculizumab; Sirolimus;
Keywords: Eculizumab; Thrombotic microangiopathy; Cancer; Hematopoetic stem cell transplantation; Eculizumab;
Keywords: Eculizumab; Atypical hemolytic uremic syndrome; Thrombotic microangiopathies; Complement activation; Eculizumab;
Keywords: Eculizumab; Complement; Therapeutics; Diagnostics; Eculizumab; CH50;
Keywords: Eculizumab; Complement; Drug; Therapeutic; Eculizumab; Indication; Clinical trial;
Keywords: Eculizumab; Atypical hemolytic uremic syndrome; Complement; Eculizumab; Terminal complement inhibitor; Thrombotic microangiopathy; AH50; Alternative pathway function; TMA; Thrombotic microangiopathy; HUS; Hemolytic uremic syndrome; aHUS; Atypical HUS; LDH; Lactate de
Keywords: Eculizumab; Antiphospholipid syndrome; Eculizumab; Kidney transplant;
Keywords: Eculizumab; Thrombotic microangiopathy; Antineoplastic drug; Vascular endothelial growth factor; Gemcitabine; Complement system; Eculizumab;
Keywords: Eculizumab; Paroxysmal nocturnal hemoglobinuria; Eculizumab; Hematopoietic stem cell transplantation;
Keywords: Eculizumab; Extracellular vesicles; Paroxysmal nocturnal hemoglobinuria; Eculizumab; Thrombosis; PNH; paroxysmal nocturnal hemoglobinuria; EV; extracellular vesicle; PFP; platelet-free plasma; TGA; thrombin generation assay; GPI; glycosylphosphatidylinositol; PS; pho
Keywords: Eculizumab; Atypical hemolytic uremic syndrome (aHUS); prophylactic therapy; plasmapheresis; eculizumab; living donor; kidney transplantation; recurrence; complement; mutation; variant; thrombotic microangiopathy (TMA); drug costs; end-stage renal disease (ESRD); cas
Keywords: Eculizumab; PNH; Complement; extravascular hemolysis; Complement receptor 1; Eculizumab;
Keywords: Eculizumab; Alternative complement pathway dysregulation; Atypical hemolytic uremic syndrome; C3 glomerulopathy; Eculizumab;
Keywords: Eculizumab; Hematopoietic stem cell transplant associated thrombotic microangiopathy; TA-TMA; Complement blockade; Eculizumab; Meningococcal infection; Meningococcal vaccine;
Keywords: Eculizumab; complement; Degos disease; eculizumab; interferon; malignant atrophic papulosis; treprostinil; vasculopathy;
Keywords: Eculizumab; Atypical hemolytic uremic syndrome; Eculizumab; Efficacy; Safety; Quality of life;
Keywords: Eculizumab; Eculizumab; Soliris; terminal complement inhibitor; atypical hemolytic uremic syndrome (aHUS); thrombotic microangiopathy (TMA); kidney disease; platelet count; hemoglobin; lactate dehydrogenase (LDH); renal function; hematologic normalization; TMA respon
Keywords: Eculizumab; Thrombotic microangiopathy; TA-TMA; Complement; Eculizumab; Hematopoietic stem cell transplant
Keywords: Eculizumab; aHUS; children; eculizumab; kidney disease; pediatric; thrombotic microangiopathy;
Keywords: Eculizumab; Catastrophic antiphospholipid syndrome; Therapeutics; Anticoagulation; Corticoids; Plasma exchange; Intravenous immunoglobulins; Rituximab; Eculizumab; Sirolimus; Review;
Keywords: Eculizumab; Heart transplantation; Heart transplant allocation; Primary graft dysfunction; Sensitization; Rituximab; Bortezomib; Eculizumab;
Keywords: Eculizumab; Thrombotic microangiopathy; Atypical hemolytic uremic syndrome; Alternative complement pathway; Eculizumab; Treatment monitoring
Keywords: Eculizumab; PNH; aHUS; CAD; Complement therapeutics; C5; Eculizumab; C3; Compstatin
Keywords: Eculizumab; Thrombotic thrombocytopenic purpura; Hemolytic uremic syndrome; ADAMTS13; Complement activation; Plasma therapy; Eculizumab;
Keywords: Eculizumab; Thrombotic thrombocytopenic purpura (TTP); congenital TTP; ADAMTS13; von Willebrand factor (vWF) protease; ultralarge vWF (ULvWF); complement; eculizumab; terminal complement pathway; atypical hemolytic uremic syndrome (aHUS); thrombotic microangiopathy (
Keywords: Eculizumab; Thrombotic microangiopathy (TMA); systemic lupus erythematosus (SLE); eculizumab; kidney biopsy; acute kidney injury (AKI); proteinuria; lupus nephritis; atypical hemolytic uremic syndrome (aHUS);
Keywords: Eculizumab; Abs; antibodies; ATG; antithymocyte globulin; BSX; basiliximab; DSA; donor-specific antibody; DTT; dithiothreitol; ECZ; eculizumab; FC; flow cytometry; HLA; human leukocyte antigen; IVIg; intravenous immunoglobulin; LCT; lymphocytotoxicity; MoAbs; monoclo
Keywords: Eculizumab; Paroxysmal nocturnal hemoglobinuria; Eculizumab; Thromboelastography; Thrombin generation test; Thrombodynamics; Global haemostatic tests
Keywords: Eculizumab; Paroxysmal Nocturnal Hemoglobinuria; Thrombosis; Eculizumab; Complement C5; Hemostasis;
Keywords: Eculizumab; Atypical hemolytic uraemic syndrome; Alternative pathway of complement system; Plasma therapy; EculizumabSíndrome hemolítico urémico atípico; Vía alternativa del complemento; Tratamiento plasmático; Eculizumab
Keywords: Eculizumab; Hemolytic uremic syndrome; Urtoxazumab; Eculizumab; Shiga toxin receptor analoguesSyndrome hémolytique urémique; Urtoxazumab; Eculizumab; Analogue des récepteurs aux Shiga toxines
Keywords: Eculizumab; Paroxysmal nocturnal hemoglobinuria; Hemolytic anemia; Alternative pathway of complement; Humanized anti-C5 monoclonal antibody; Eculizumab; C3 blockade; C1 inhibition; Bone marrow failure;
Keywords: Eculizumab; Eculizumab; Complement therapeutics; PNH; aHUS; C3; C5; Compstatin;
Keywords: Eculizumab; Atypical haemolytic uraemic syndrome; Eculizumab; Complement; Thrombotic microangiopathySíndrome hemolítico urémico atípico; Eculizumab; Complemento; Microangiopatía trombótica
Keywords: Eculizumab; Complement; Therapy; Placenta; Eculizumab; Paroxysmal nocturnal hemoglobinuria;
Keywords: Eculizumab; children; eculizumab; neurologic involvement; renal disease; Shiga toxin-producing Escherichia coli-associated hemolytic–uremic syndrome
Keywords: Eculizumab; Haemolytic uremic syndrome; skin; eculizumab; thrombotic microangiopathy; plasma exchange; case report;
Keywords: Eculizumab; Atypical hemolytic uremic syndrome; eculizumab; discontinuation;
Keywords: Eculizumab; Atypical HUS; Transfusion practices; Eculizumab;
Keywords: Eculizumab; Eculizumab; C3 glomerulopathies; Atypical hemolytic uremic syndrome; Complement; Anti-neutrophil cytoplasmic autoantibody;
Keywords: Eculizumab; Eculizumab; Plasma exchange; Post renal transplant thrombotic microangiopathy
Keywords: Eculizumab; Thrombotic microangiopathy; Eculizumab; CH50; Eculizumab pharmacokinetics; Hematopoietic stem cell transplant
Keywords: Eculizumab; Atypical hemolytic uremic syndrome; eculizumab; complement; thrombotic microangiopathy;
Keywords: Eculizumab; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura; Hemolytic uremic syndrome; Shiga toxin; Complement dysregulation; Eculizumab
Keywords: Eculizumab; Atypical hemolytic uremic syndrome; Complement; Eculizumab;